A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Bibliographic Details
Main Authors: Camidge, D. Ross, Berge, Eamon M., Doebele, Robert C., Ballas, Marc S., Jahan, Thierry, Haigentz, Missak, Hoffman, David, Spicer, James, West, Howard, Lee, Pablo, Yang, Ling, Joshi, Adarsh, Gao, Ling, Yurasov, Sergey, Mita, Alain
Format: Online
Language:English
Published: Lippincott Williams & Wilkins 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165478/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165478/

Similar Items